The Court has preliminarily approved two proposed class action settlements in the Metformin Marketing and Sales Practice Litig. (2:20-CV-2324) filed in the US District Court for the District of New Jersey. Kanner & Whiteley has been appointed as class counsel for these class settlements. The settlements reflect months of careful negotiation and extensive documentation prepared and filed by our team and provide an important path toward fair compensation for individuals affected by contaminated medications.
This consolidated action combines economic loss claims from plaintiffs who allege they were exposed to carcinogens found in certain diabetes medications.
Class notice will be disseminated shortly, and a fairness hearing has been scheduled in August 2026.